BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27667173)

  • 1. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway.
    Cao S; Xia M; Mao Y; Zhang Q; Donkor PO; Qiu F; Kang N
    Int J Oncol; 2016 Nov; 49(5):2075-2087. PubMed ID: 27667173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma.
    Cao S; Huang Y; Zhang Q; Lu F; Donkor PO; Zhu Y; Qiu F; Kang N
    Apoptosis; 2019 Feb; 24(1-2):33-45. PubMed ID: 30430397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways.
    Kang N; Zhang JH; Qiu F; Tashiro S; Onodera S; Ikejima T
    Cancer Lett; 2010 Aug; 294(2):147-58. PubMed ID: 20202741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab enhances oridonin-induced apoptosis through mitochondrial pathway and endoplasmic reticulum stress in laryngeal squamous cell carcinoma cells.
    Kang N; Cao S; Jiang B; Zhang Q; Donkor PO; Zhu Y; Qiu F; Gao X
    Toxicol In Vitro; 2020 Sep; 67():104885. PubMed ID: 32407876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
    Gong JH; Liu XJ; Li Y; Zhen YS
    Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
    Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
    Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of caspase-9 by oridonin, a diterpenoid isolated from Rabdosia rubescens, augments apoptosis in human laryngeal cancer cells.
    Kang N; Cao SJ; Zhou Y; He H; Tashiro S; Onodera S; Qiu F; Ikejima T
    Int J Oncol; 2015 Dec; 47(6):2045-56. PubMed ID: 26648189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
    Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
    Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
    Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells.
    Ren K; Zhang W; Wu G; Ren J; Lu H; Li Z; Han X
    Biomed Pharmacother; 2016 Dec; 84():1748-1759. PubMed ID: 27876206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells.
    Yang H; Wang J; Khan S; Zhang Y; Zhu K; Zhou E; Gong M; Liu B; Kan Q; Zhang Q
    Anticancer Drugs; 2022 Jan; 33(1):e444-e452. PubMed ID: 34520434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
    Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
    Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
    Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells.
    Kang N; Zhang JH; Qiu F; Chen S; Tashiro S; Onodera S; Ikejima T
    J Nat Prod; 2010 Jun; 73(6):1058-63. PubMed ID: 20496901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; BarĂ³n AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
    Tao X; Lu Y; Qiu S; Wang Y; Qin J; Fan Z
    Cancer Lett; 2017 Nov; 408():33-42. PubMed ID: 28823958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.